Fig. 3

Adipocyte exosomal LncRNAs contributes to MM drug resistance. a. Quantitative real-time PCR analysis shows the relative expression of a panel of LncRNAs in MM cells exposed to exosomes derived from nAD or MMADs. b. Kaplan–Meier analysis shows the overall survival of MM patients with low or high expression of LOC606724 (LOC, n = 400) or SNHG1 (n = 400) in MM cells analyzed from MMRF’s CoMMpass database. c & d. The expression of LOC (c, n = 50) or SNHG1 (d, n = 63) in MM patients who responded (Responders) or did not respond (Non-Responders) to bortezomib-based treatment from CoMMpass database. e & f. ARP-1 cells were overexpressed with LOC or SNHG1. Cells transfected with empty vector (Vec) served as control. e. Quantitative real-time PCR analysis shows the relative expression of LOC and SNHG1 in ARP-1 cells overexpressed with respective genes. f. Annexin V-binding assay shows the percentages of apoptotic ARP-1 cells overexpressed with LOC or SNHG1 treated with vehicle or bortezomib (BTZ, 5 nM) for 24 h. g & h. MMADs were infected with lentiviral particles carrying shRNAs targeting LOC or SNHG1. g. Quantitative real-time PCR analysis shows the relative level of exosomal LOC or SNHG1 collected from shLOC or shSNHG1 MMADs. h. Annexin V-binding assay shows the percentages of apoptotic MM cells treated with vehicle or 5 nM bortezomib for 24 h with shLOC or shSNHG1 MMAD-derived exosomes. MMADs treated with vehicle or non-target shRNA (shCtrl) served as control. Data shown as mean ± SD. *P < 0.05; **P < 0.01; ****P < 0.0001. P values were determined by Student t-tests for comparison of two groups and one-way ANOVA for comparison of more than two groups